systems biology – Ayurved Healing

Multi-Omics Approaches to Validating Rasayana: Genomics, Proteomics, and Metabolomics

Dr. Meera Iyer — Mon, 17 Aug 2026 07:30:00 +0000

Multi-Omics Approaches to Validating Rasayana: Genomics, Proteomics, and Metabolomics

Rasayana is the rejuvenative branch of Ayurveda concerned with longevity, strength, memory, resilience, nourishment, complexion, voice, sensory clarity, and resistance to illness. These are broad, system-wide outcomes rather than single-target effects, so the most suitable modern research tools are those that can observe many biological layers at once.

Multi-omics research combines high-throughput approaches such as genomics, transcriptomics, proteomics, metabolomics, and sometimes microbiome profiling. For rasayana research, this approach is valuable because it can map how a herb, formulation, diet, or regimen influences gene expression, protein pathways, metabolites, immune signals, oxidative stress, and tissue-level physiology together rather than in isolation.

Why Multi-Omics Fits Rasayana

The classical logic of rasayana is closer to systems biology than to a one-drug, one-target pharmacology model. A rasayana formulation may contain many botanicals, minerals, fats, sugars, and processing steps, and its intended effect is not merely symptom suppression but support of dhatu quality, agni, srotas, bala, medha, and ojas.

Genomics can help examine inherited differences, including whether prakriti-based stratification corresponds to biological variation.
Transcriptomics can reveal changes in gene expression after exposure to a rasayana herb or formulation.
Proteomics and protein-level assays can track stress proteins, enzymes, receptors, inflammatory mediators, and repair pathways.
Metabolomics can capture changes in amino acids, lipids, energy metabolites, oxidative markers, and small molecules closest to functional physiology.
Integrated multi-omics can connect these layers into a systems-level map that is more suitable for complex Ayurvedic interventions.

Charaka describes rasayana as that which supports long life, memory, intellect, freedom from disease, youthful qualities, complexion, voice, strength of body, and strength of the senses. These classical outcomes cannot be reduced to one biomarker. They require a research design that can follow coordinated changes across metabolism, immunity, tissue function, and cognition.

Classical Grounding: Rasayana as a Tissue-Level Strategy

In classical Ayurveda, rasayana is not only a category of herbs. It includes diet, formulations, cleansing preparation when appropriate, daily conduct, and individualized administration. Its central aim is to improve the quality of nourishment and tissue formation so that the body maintains strength, clarity, and resistance over time.

This makes dhatu quality, agni, srotas, and ojas important interpretive categories for modern research. A contemporary protocol can translate these into measurable domains such as nutritional status, inflammatory balance, oxidative stress, mitochondrial function, immune markers, cognitive testing, sleep, physical performance, and metabolomic signatures.

Genomics and Ayurgenomics

Ayurgenomics is one of the most important bridges between Ayurveda and omics science. It examines whether Ayurvedic classifications such as prakriti correspond to measurable genetic, gene-expression, biochemical, and metabolic differences. This is especially relevant for rasayana because rejuvenative interventions are traditionally individualized.

Published work from Indian Ayurgenomics initiatives has examined prakriti in relation to genome-wide markers, gene-expression differences, hypoxia-response biology, metabolic traits, and plasma metabolomic patterns. This does not make prakriti a substitute for clinical diagnosis, but it gives researchers a practical way to stratify participants before testing rasayana interventions.

For rasayana trials, this matters because two people may respond differently to the same herb or formulation. Genomic and prakriti-aware stratification can help identify responders, non-responders, safety signals, and subgroup-specific metabolic patterns that would be blurred in an unstratified trial.

Transcriptomic Signals from Rasayana-Associated Botanicals

Transcriptomics is useful for rasayana research because it shows how cells alter gene expression after exposure to a botanical extract or formulation. These data can help identify whether a candidate rasayana influences pathways related to stress response, inflammation, neural signaling, cell survival, transport, or metabolism.

Ashwagandha (Withania somnifera)

Ashwagandha is widely used in Ayurveda as a strengthening and restorative herb. Cell-based work with Withania somnifera extracts has documented effects on neuronal and glial models, including changes in markers related to differentiation, stress proteins, extracellular matrix modulation, and cellular resilience.

In neuroblastoma and glioma cell models, ashwagandha water extract has been examined for protection against glutamate-induced excitotoxicity and for effects on neuronal differentiation markers. Reported protein and pathway markers include HSP70, mortalin, NCAM, PSA-NCAM, neurofilament proteins, matrix metalloproteinases, Akt phosphorylation, cyclin D1, and Bcl-xl. These are not whole-human rasayana outcomes, but they provide mechanistic entry points for medhya and balya research.

More recent gene-expression work with Withania somnifera root preparations has examined pathways connected with oxidative response, cellular stress adaptation, inflammation, and neuronal protection. For rasayana validation, the most responsible use of these findings is to design better human trials with transcriptomic endpoints paired with clinical measures such as sleep, stress, fatigue, cognition, inflammatory markers, and safety labs.

Brahmi and Bacopa monnieri

Bacopa monnieri is widely used as Brahmi in modern Ayurveda and is commonly associated with medhya effects. Classical Charaka descriptions of medhya rasayana specifically list Mandukaparni, Yashtimadhu, Guduchi, and Shankhapushpi; modern regional practice also commonly uses Bacopa monnieri under the name Brahmi.

RNA-sequencing work in differentiated SH-SY5Y human neuroblastoma cells found that Bacopa monnieri extract altered gene-expression patterns related to mRNA translation regulation, transmembrane transport, protein misfolding, and oxidative stress response. In the same experimental context, Bacopa exposure was also examined against hydrogen-peroxide-induced toxicity. These findings fit the research question of how medhya herbs may influence neuronal stress and cellular adaptation, while still requiring clinical correlation for memory and cognition claims.

Proteomics and Protein-Level Readouts

Proteomics and targeted protein assays are important because gene-expression shifts do not always translate into functional protein changes. Rasayana research benefits from measuring enzymes, inflammatory proteins, heat-shock proteins, apoptotic markers, mitochondrial proteins, immune mediators, and tissue-repair markers alongside transcriptomic and metabolomic data.

Ashwagandha Protein Endpoints

Ashwagandha cell studies have used protein markers such as HSP70, mortalin, NCAM, PSA-NCAM, neurofilament proteins, MMP-2, MMP-9, cyclin D1, Bcl-xl, and Akt phosphorylation to examine stress response, differentiation, proliferation, and cellular survival. These protein endpoints are useful because they help connect the traditional categories of bala, medha, and rasayana support with measurable cellular processes.

Future proteomic work on ashwagandha should move beyond single-cell models and include human samples, standardized extracts, batch phytochemical fingerprints, clinically meaningful endpoints, and safety monitoring. A strong design would pair proteomic panels with sleep scores, fatigue scores, inflammatory markers, liver enzymes, thyroid-related safety markers when relevant, and participant stratification by constitution and baseline health status.

Triphala as a Multi-Component Formulation

Triphala is a classical three-fruit formulation composed of Haritaki, Bibhitaki, and Amalaki. Although many modern experiments focus on isolated disease models, Triphala is especially relevant to systems-style research because it combines multiple fruits rich in polyphenols, tannins, and other small molecules.

In human colon cancer cell and colon cancer stem-cell models, methanolic Triphala extract has been evaluated with phytochemical analysis, antioxidant testing, proliferation assays, apoptosis markers, and protein-level Western blot endpoints. Reported molecular markers include c-Myc, cyclin D1, Bax, Bcl-2, and cleaved PARP. For rasayana research, this demonstrates how a classical formulation can be profiled through chemical fingerprints and multi-marker protein panels rather than one isolated constituent.

For more on Triphala’s gut-focused research context, see our article on How Triphala Reshapes Your Gut.

Metabolomics: The Biochemical Fingerprint

Metabolomics is especially well suited to rasayana because it captures small-molecule changes close to the functional state of the body. While genomics indicates inherited potential and transcriptomics indicates cellular messaging, metabolomics reflects ongoing shifts in energy metabolism, amino acid handling, lipid pathways, oxidative balance, and gut-derived metabolites.

Withania-Bacopa Metabolomic Profiling

A recent NMR-based metabolomic investigation examined a combined Withania somnifera and Bacopa monnieri formulation in SH-SY5Y human neuroblastoma cells. The formulation was chemically characterized by UHPLC-HRMS/MS and then evaluated through endometabolomic and exometabolomic profiling.

The metabolomic analysis identified changes in amino acid pathways, neurotransmission-related metabolites, energy-metabolism signals, and oxidative-stress-related biochemical patterns. These findings are useful for rasayana research because they show how a multi-herb preparation can be mapped as a biochemical network rather than as a single isolated molecule.

Prakriti and Metabolomic Stratification

Metabolomic work on prakriti phenotypes has reported differences in plasma metabolic pathways among constitution groups. This supports a practical research principle: rasayana trials should record baseline constitution, diet, digestive status, sleep, age, sex, and metabolic health because these may influence metabolomic response.

A rasayana metabolomics trial that ignores baseline diversity may miss the very individuality that Ayurveda considers central. A better design would compare pre-treatment and post-treatment metabolomes within each participant, then examine whether response clusters align with prakriti, age, metabolic state, and clinical outcomes.

Polyherbal Rasayana: Chyawanprash as a Formulation Case

Chyawanprash is one of the best-known classical rasayana formulations, traditionally centered on Amalaki and prepared with many supporting ingredients. Modern reviews describe it as a polyherbal health supplement in which Amla is the prime ingredient and numerous additional botanicals contribute to the final formulation.

For multi-omics research, Chyawanprash should be studied as a whole formulation, not only as Amalaki. The classical concept of yoga, or formulation design, implies that the combined preparation may have a distinct biological profile. A suitable omics study would therefore compare the complete formulation with key ingredients, control preparations, and matched dietary controls.

Clinical and experimental work on Chyawanprash has focused mainly on immunity-related parameters, general health, infection-related symptom patterns, and inflammatory models. These provide useful endpoints for future multi-omics studies: immune-cell transcriptomics, cytokine panels, plasma metabolomics, gut microbiome profiling, oxidative markers, and clinical records of seasonal respiratory symptoms.

Amalaki Rasayana and Telomerase Research

Amalaki is central to many rasayana preparations and is also used as a rasayana in its own right. Human work on Amalaki Rasayana has examined telomerase activity and telomere length in peripheral blood mononuclear cells from healthy aged adults.

In that trial context, telomerase activity increased after Amalaki Rasayana administration, while telomere length did not show a discernible increase over the observation period. This is an important example of how rasayana claims can be examined carefully: a molecular aging-related marker may move without automatically proving lifespan extension or broad anti-aging benefit.

Integrated Multi-Omics: The Systems Biology Approach

The strongest rasayana research design is not a single omics platform but an integrated model. A well-built study can combine baseline prakriti assessment, standardized formulation chemistry, transcriptomics, proteomics, metabolomics, microbiome profiling, clinical endpoints, and safety labs.

For example, a Chyawanprash or Amalaki Rasayana trial could collect blood, stool, diet records, sleep data, symptom logs, and validated quality-of-life measures at baseline and follow-up. The omics layers could then be integrated to see whether immune, metabolic, antioxidant, and microbial shifts move together with clinically meaningful outcomes.

Bioinformatics platforms such as MetaboAnalyst, iDEP, and MOFA-family tools can support pathway analysis, transcriptomic interpretation, metabolomic integration, and multi-omics factor analysis. These tools are especially useful when the research question is not one isolated molecule but a coordinated biological signature.

Methodological Requirements for Rasayana Omics Studies

Rasayana research needs stricter methodology than ordinary supplement screening because the interventions are complex and traditionally individualized. Without standardization, stratification, and clinical endpoints, omics data can become large but difficult to interpret.

Requirement	Why It Matters	Good Practice
Botanical authentication	Incorrect plant identity can invalidate the entire omics signature.	Use authenticated raw materials, voucher specimens, and pharmacopoeial standards where available.
Batch fingerprinting	Polyherbal formulations vary with source, season, processing, and manufacturer.	Report HPTLC, LC-MS, NMR, or other chemical fingerprints for every batch used.
Clear formulation details	Classical names may hide large differences in ingredient ratio and preparation method.	Report ingredients, proportions, extract type, excipients, dose, duration, and administration method.
Participant stratification	Rasayana is traditionally individualized.	Record prakriti, age, sex, diet, digestive status, sleep, baseline metabolic health, and medication use.
Multi-layer sampling	One biomarker cannot represent a rasayana effect.	Combine transcriptomics, targeted protein panels, metabolomics, microbiome data, and clinical outcomes.
Clinical linkage	Molecular movement alone is not the same as patient benefit.	Pair omics findings with validated measures such as cognition tests, fatigue scales, sleep scores, infection records, inflammatory markers, and quality-of-life tools.
Safety monitoring	Natural products can interact with medicines or be unsuitable for some people.	Monitor adverse events, liver and kidney function where appropriate, pregnancy status, comorbidities, and concurrent medications.

What the Current Evidence Supports

The most useful conclusion from current omics-oriented work is that rasayana-associated herbs and formulations can be studied as multi-target biological interventions. The strongest evidence is still pathway-mapping and mechanism-building rather than definitive clinical proof of classical outcomes.

Systems-level mapping is appropriate: Rasayana interventions are complex, and multi-omics can capture broad molecular patterns more effectively than a single biomarker.
Prakriti can guide stratification: Ayurgenomics work supports the idea that constitution-based grouping can be explored biologically and may improve trial design.
Medhya herbs can be examined mechanistically: Ashwagandha and Bacopa research provides cellular and molecular endpoints relevant to neuronal stress, differentiation, oxidative response, and metabolic adaptation.
Formulation-level research is necessary: Chyawanprash and Triphala should be profiled as complete formulations because their biological signatures may differ from isolated ingredients.
Metabolomics is especially valuable: Metabolite patterns can connect rasayana theory with measurable changes in energy metabolism, amino acid pathways, oxidative balance, and immune-metabolic function.

Our article on Nrf2 Pathway Activation by Ayurvedic Herbs examines one specific antioxidant-response pathway that can be integrated into broader rasayana omics research.

Boundaries of Interpretation

Omics can reveal biological signatures, but rasayana validation still requires careful clinical research. Cell-line experiments, animal models, protein panels, and metabolomic shifts are useful for mechanism building; they should be connected to human outcomes before making strong claims about longevity, disease prevention, immunity, or cognitive improvement.

Lifespan: Aging-related markers such as telomerase activity, oxidative stress, and mitochondrial metabolism are not the same as demonstrated human lifespan extension.
Clinical outcomes: A transcriptomic or metabolomic change should be paired with validated clinical endpoints.
Dose and duration: Rasayana protocols may involve specific preparation, diet, timing, and duration; short supplement trials may not represent the full classical method.
Individualization: Constitution, digestion, age, illness, medication use, and lifestyle can influence response and safety.
Quality control: The same classical name can refer to products of very different quality, composition, and potency.

Future Directions

The next phase of rasayana research should combine classical precision with modern measurement. The goal should not be to force Ayurveda into a single-target drug model, but to test its systems-level claims with rigorous, transparent, reproducible tools.

Longitudinal multi-omics: Track changes over weeks and months to see how rasayana responses develop over time.
Single-cell omics: Identify which immune, neural, or metabolic cell populations respond most strongly.
Microbiome integration: Study how formulations such as Triphala and Chyawanprash interact with gut microbial metabolism.
Network pharmacology: Combine phytochemical data with pathway modeling to identify plausible multi-target effects.
Prakriti-stratified trials: Test whether Ayurvedic constitution improves prediction of response and safety.
Open data and batch reporting: Publish omics datasets with formulation fingerprints so that results can be compared across studies.

Perspective for the Field

Multi-omics gives rasayana research a practical way to examine what classical Ayurveda described in qualitative language: systemic nourishment, resilience, strength, clarity, and balanced tissue function. The best use of these tools is neither blind acceptance nor dismissal, but careful mapping of what changes, in whom, at what dose, for how long, and with what clinical meaning.

When used responsibly, genomics, transcriptomics, proteomics, metabolomics, and systems biology can help build a more mature evidence base for rasayana. They can also protect the field from overstatement by separating molecular plausibility from clinical proof. This balanced approach respects both the classical tradition and the standards needed for modern healthcare research.

Medical Disclaimer: This article is for educational purposes only. Rasayana herbs and formulations should be used under the guidance of a qualified Ayurvedic practitioner and, when relevant, a licensed healthcare provider. Do not use rasayana preparations as a substitute for prescribed treatment. Consult your healthcare provider before starting any supplement, especially if you are pregnant, have a medical condition, have liver, kidney, thyroid, autoimmune, or metabolic concerns, or take prescription medicines.

References

Network Pharmacology of Triphala: How Systems Biology Decodes a 3000-Year Formula

Dr. Meera Iyer — Thu, 02 Apr 2026 09:00:00 +0000

The familiar “one drug, one target” model is useful, but it is not a complete description of pharmacology. Many effective medicines influence more than one protein or pathway, while complex botanical preparations contain numerous constituents whose concentrations, absorption, metabolism, and interactions vary. Triphala is therefore a suitable subject for network pharmacology, provided that computational predictions are kept separate from experimentally demonstrated effects and clinical outcomes.

Triphala is an Ayurvedic formulation made from the fruits of Amalaki, Bibhitaki, and Haritaki. Analytical work has detected multiple phenolic acids and hydrolysable tannins in the combined preparation, including gallic acid, ellagic acid, chebulagic acid, and chebulinic acid. This chemical diversity can generate many plausible compound-target relationships, but the number of predicted links is not itself evidence that Triphala treats every disease associated with those targets.

What Network Pharmacology Actually Examines

Network pharmacology integrates pharmacology, systems biology, chemical information, and network analysis. Instead of representing a medicine as one molecule connected to one protein, it may connect several compounds to predicted or experimentally reported targets, protein-protein interactions, biological pathways, and disease-associated genes. Andrew Hopkins introduced the term in 2007 and developed the framework in a 2008 review that emphasized the importance of polypharmacology and multi-target drug action.

A typical herbal network study first compiles reported constituents from chemical databases or laboratory analyses. It then predicts protein targets, intersects them with disease-associated genes, constructs interaction networks, performs pathway-enrichment analysis, and may use molecular docking to estimate whether selected compounds can fit particular protein-binding sites. Each step is hypothesis-generating. Database inclusion, oral-bioavailability filters, target-prediction algorithms, and docking scores can all alter the final network.

The Three Fruits and Verified Chemical Markers

The Ayurvedic Pharmacopoeia of India identifies the botanical sources of the three fruits, while the Ayurvedic Formulary of India includes Triphala preparations. A commonly described Triphala churna combines the dried fruit materials in equal proportions. Botanical identity matters because substitution, incorrect plant parts, processing differences, and storage can change the chemical profile.

Fruit	API Botanical Source	Part Used	Representative Constituents Reported in Triphala or Its Ingredients
Amalaki	Emblica officinalis Gaertn.	Fruit	Gallic acid, ellagic acid, gallotannins, flavonoids
Bibhitaki	Terminalia bellirica Roxb.	Fruit	Gallic acid, ellagic acid, chebulagic acid and related tannins
Haritaki	Terminalia chebula Retz.	Fruit	Chebulagic acid, chebulinic acid, gallic acid, ellagic acid

One HPLC-DAD analysis of Triphala churna quantified eight markers: gallic acid, methyl gallate, ethyl gallate, chebulagic acid, tetra-O-galloyl glucose, ellagic acid, chebulinic acid, and penta-O-galloyl glucose. These compounds are useful for chemical characterization, but no single marker by itself represents the full Ayurvedic formulation or guarantees a clinical effect.

What the Published Network Studies Found

The traceable network literature does not support the frequently repeated claim that Triphala has exactly 275 active compounds acting on exactly 47 core targets. Different studies use different databases, eligibility filters, disease models, and laboratory methods, so their compound and target counts are not interchangeable.

The 2015 Anticancer-Association Analysis

A 2015 paper indexed under PMID 26477351 used network pharmacology to examine anticancer-related associations of Triphala. A related open-access analysis reported 60 targets connected through database relationships to 24 disease categories and 130 disease indications. Those figures describe a computational network assembled from available data; they do not mean that Triphala has been clinically proven against 130 diseases.

The 2018 Gynecological-Cancer Study

A 2018 study selected 50 candidate Triphala compounds and 55 major targets for a gynecological-cancer network. Its pathway analysis emphasized MAPK/ERK, PI3K/Akt/mTOR, and NF-kappaB/p53-related signaling. The investigators then tested Triphala in ovarian, cervical, and endometrial cancer cell lines and reported reduced proliferation and increased apoptosis. This is a stronger design than docking alone because it adds cell-based validation, but it remains preclinical and does not establish safety or efficacy in people with cancer.

The 2020 Angiogenesis Study

A 2020 investigation evaluated more than 15 Triphala phytochemicals through docking and experiments in human umbilical vein endothelial cells. It examined VEGF/VEGFR2-related signaling, endothelial markers, growth factors, and cell migration. The work supports further investigation of anti-angiogenic mechanisms in laboratory models; it is not a clinical treatment study and should not be used to replace oncology care.

The 2024 Obesity-Focused Network

A 2024 obesity analysis retrieved 147 candidate compounds from databases: 92 associated with Phyllanthus emblica, 41 with Terminalia chebula, and 14 with Terminalia bellirica. AKT1 and PPARG were among the highlighted targets, and selected constituents such as beta-sitosterol, luteolin, quercetin, kaempferol, ellagic acid, and phyllanthin were examined by docking. These results propose metabolic hypotheses; they do not establish weight-loss efficacy or a standard therapeutic dose.

Polypharmacology Is Not Proof of Coordinated Synergy

Polypharmacology means that one drug or preparation can affect multiple biological targets. Polypharmacy means the concurrent use of multiple medicines. Triphala fits the first concept more readily than the second, but its natural origin does not prove that every constituent acts cooperatively or that adverse effects are automatically counterbalanced. Synergy, additivity, antagonism, absorption, metabolism, and toxicity must each be evaluated experimentally.

Network diagrams can help prioritize compounds and pathways for testing, yet the presence of a highly connected “hub” does not demonstrate that an ingested dose reaches that protein at an effective concentration in human tissue. Tannins and other polyphenols may be transformed during digestion, bind to food components, or be metabolized by the intestine, liver, and gut microbiota. Exposure data and controlled clinical studies are therefore necessary before target maps can be translated into treatment claims.

Classical Ayurvedic Context

Classical Ayurveda does not describe Triphala through genes, cytokines, or molecular docking. It evaluates substances through frameworks such as rasa, guna, virya, vipaka, prabhava, dose, preparation, timing, digestive capacity, season, constitution, and disease state. Modern pathway terminology may be used as a research tool, but it should not be presented as a direct molecular translation of the doshas.

The Charaka Samhita, in the Rasayana section of Chikitsa Sthana, describes regimens using Haritaki, Bibhitaki, and Amalaki with specified accompaniments. This provides a classical basis for Triphala-related Rasayana use. Triphala is commonly characterized as a tridoshic Rasayana in Ayurvedic literature, but assigning each fruit to one cytokine, organ system, or signaling pathway is not a classical doctrine and has not been established as a one-to-one biological map.

Triphala and the Gut Microbiome

Microbiome work offers a plausible route by which some Triphala constituents may be transformed after ingestion. A 2018 synbiotic study used anaerobic batch cultures, a simulated human gastrointestinal model, and Drosophila. Another in-vitro investigation of digestive herbs reported an increase in the relative abundance of some butyrate-producing bacteria during Triphala fermentation. These models are useful for mechanism discovery but do not reproduce the full complexity of long-term human use.

A small randomized, double-blind, placebo-controlled pilot published in 2020 gave 2,000 mg of Triphala daily for four weeks. Thirty-one healthy adults were randomized and 29 completed the study. Microbiome responses were highly individualized, and no bacterial taxon changed uniformly across all participants. This finding argues against presenting Triphala as a predictable method for increasing specific genera such as Lactobacillus or Bifidobacterium in every person.

Ellagitannins and ellagic acid can be converted by gut bacteria into urolithins, but this capacity varies among individuals according to their microbial communities. Urolithin biology is an active research area; it does not establish that every Triphala user produces the same metabolite profile or receives the same systemic effect. Claims that probiotic co-supplementation reliably strengthens Triphala therefore require direct clinical testing.

Practical Use, Quality, and Safety

Product selection should begin with authenticated botanical material and transparent manufacturing controls rather than a large number of predicted targets on a label. A quality-conscious product should identify the three ingredients and plant parts, provide batch information, and come from a manufacturer that tests identity, microbial quality, and relevant contaminants. Whole-powder churna and concentrated extracts are not dose-equivalent merely because both are called Triphala.

There is no network-pharmacology calculation that establishes a universal dose, twice-daily schedule, bedtime timing, or 30-day self-test. Appropriate use depends on the preparation, purpose, individual tolerance, diet, bowel pattern, concurrent illness, and medicines. Triphala can produce gastrointestinal effects, including loose stools, particularly when the amount exceeds individual tolerance. Laboratory work has also found inhibition of several cytochrome P450 enzymes, and a rat study found altered exposure to probe drugs, so medication interactions remain a practical concern.

Pregnant or breastfeeding people, children, people with persistent diarrhea or dehydration, those preparing for surgery, and anyone taking prescription medicines should seek individualized guidance. Triphala should not be used to self-treat cancer, diabetes, liver disease, inflammatory bowel disease, or another diagnosed condition. Consult a qualified Ayurvedic practitioner and an appropriate healthcare provider before using it therapeutically, especially when ongoing medical treatment is involved.

A Balanced Interpretation

Network pharmacology gives Triphala research a structured way to organize chemical constituents, predicted targets, interaction networks, and testable pathways. Its most valuable role is to generate hypotheses and guide laboratory or clinical study design. The available literature includes computational analyses, cell experiments, simulated-gut systems, animal models, and a small human microbiome pilot, but these levels of evidence should not be merged into a single claim of broad clinical efficacy.

The scientifically defensible conclusion is that Triphala is a chemically complex classical formulation with several experimentally investigated constituents and multiple plausible biological interactions. Its traditional Ayurvedic use, analytical chemistry, network predictions, and emerging laboratory findings can be discussed together, provided that each is represented on its own terms. That approach preserves both classical accuracy and scientific rigor without turning a network diagram into a substitute for clinical evidence.

This article is for educational purposes and does not provide diagnosis or treatment. Consult a qualified Ayurvedic practitioner and a licensed healthcare provider for advice suited to your health, medicines, and intended use.

References

Srotas: How Ayurveda’s Channel System Maps to Modern Physiology

Dr. Meera Iyer — Mon, 23 Feb 2026 01:41:12 +0000

Srotas in Ayurveda: Classical Channel Theory and Modern Physiological Comparisons

Srotas are the pathways through which substances, nourishment, wastes, impulses, and transformative processes are understood to move within the Ayurvedic body. The principal classical account appears in the Charaka Samhita, Vimana Sthana, Chapter 5. Charaka describes srotas as channels that carry dhatus while they are undergoing transformation and states that bodily structures neither arise nor decline independently of these pathways. This is a functional Ayurvedic model of transport, exchange, nourishment, and elimination rather than a catalogue of vessels identical to modern anatomy.

Modern physiological systems can help readers visualize selected functions of srotas, but the comparison must remain cautious. A srotas may include an organ, its supporting pathways, the material carried, and the physiological activity associated with them. It should therefore not be equated strictly with one artery, duct, nerve, hormone pathway, or organ system. Classical Ayurvedic diagnosis also evaluates dosha, dhatu, mala, agni, symptoms, causative factors, and the affected srotas together.

The Classical Meaning of Srotas

In Charaka’s account, the varieties of srotas are potentially innumerable because there are as many channels as there are embodied structures and processes. For practical clinical discussion, the text names thirteen principal groups: three concerned with the intake of essential supports, seven associated with the seven dhatus, and three concerned with elimination. These are pranavaha, udakavaha, annavaha, rasavaha, raktavaha, mamsavaha, medovaha, asthivaha, majjavaha, shukravaha, mutravaha, purishavaha, and svedavaha srotas.

The text gives a mula, or principal root site, for each major srotas. Mula does not always mean a single anatomical point of origin in the modern sense. It can indicate a vital seat, controlling region, source, or structure whose injury or dysfunction seriously affects the channel. Charaka also uses related terms such as sira, dhamani, rasayani, nadi, pantha, marga, ashaya, and niketa for different pathways, spaces, conduits, or abodes. The srotas are described as tubular or branching, large or minute, long, and similar in colour to the material they carry.

The Thirteen Principal Srotas in Charaka

The following descriptions preserve Charaka’s stated root sites and symptoms while using modern physiology only as an explanatory comparison. The modern column should be read as a functional analogy, not as a claim that the classical and biomedical categories are identical.

1. Pranavaha Srotas

Charaka gives hridaya and mahasrotas as the roots of pranavaha srotas. Hridaya is commonly translated as heart, while mahasrotas denotes the great internal passage and is often understood in relation to the alimentary tract. Disturbance is recognized through excessively prolonged, restricted, forceful, shallow, frequent, noisy, or painful breathing. These features justify comparison with respiratory function and its close relationship with circulation, but pranavaha srotas is broader than the bronchial tree alone.

2. Udakavaha Srotas

The roots of udakavaha srotas are talu and kloma. Talu is the palate; the precise modern anatomical identity of kloma remains uncertain and should not be fixed confidently as either pancreas or lung. Charaka associates disturbance with dryness of the tongue, palate, lips, throat, and kloma, together with excessive thirst. A cautious modern comparison is the integrated regulation of thirst, body water, mucosal moisture, and fluid balance rather than a single endocrine pathway.

3. Annavaha Srotas

The roots of annavaha srotas are amashaya and the left flank. The text lists lack of desire for food, loss of appetite or taste, impaired digestion, and vomiting among its signs of disturbance. Its closest modern comparison is the upper gastrointestinal process of receiving, digesting, and moving food, although the Ayurvedic concept also includes agni and the suitability, quantity, and timing of food.

4. Rasavaha Srotas

The roots of rasavaha srotas are hridaya and the ten dhamanis. Rasa is the first of the seven dhatus and is associated with immediate nourishment and distribution after digestion. Plasma circulation, lymphatic movement, tissue perfusion, and interstitial exchange can serve as partial modern analogies, but rasa dhatu is not simply blood plasma or lymph. Charaka directs the reader to the disorders of rasa dhatu when identifying disturbance of its channels.

5. Raktavaha Srotas

The roots of raktavaha srotas are yakrit and pliha, generally translated as liver and spleen. Rakta is closely associated with blood, colour, vitality, and heat in Ayurvedic physiology. The liver and spleen also have major roles in modern blood metabolism and immune function, making hematologic and vascular processes useful comparisons. The classical category nevertheless includes a wider Ayurvedic understanding of rakta and should not be reduced to red blood cells or the cardiovascular system alone.

6. Mamsavaha Srotas

The roots of mamsavaha srotas are snayu and tvak. Snayu can refer to fibrous binding structures such as tendons and ligaments, while tvak means skin. Mamsa denotes muscle or flesh and its supporting form. Muscles, fascia, tendons, connective-tissue interfaces, and skin provide a reasonable visual comparison, but the classical root statement does not establish a modern fascial network theory.

7. Medovaha Srotas

Charaka places the roots of medovaha srotas in the two vrikkas and vapavahana. Vrikkas are usually rendered as kidneys, and vapavahana is commonly interpreted in relation to the omentum or abdominal fat-bearing structure. Meda denotes adipose tissue and related unctuous, stabilizing functions. Adipose storage and metabolic regulation are useful modern parallels, but claims that the classical root was based on the renin-angiotensin system or specific lipid hormones go beyond the text.

8. Asthivaha Srotas

The roots of asthivaha srotas are meda and jaghana, the pelvic or hip region. Asthi denotes bone. The skeletal system, bone remodelling, mineral balance, and marrow-bearing structures are modern areas that can help explain its bodily relevance. Brittle nails, hair loss, or dental problems should not be presented as direct proof of calcium deficiency or isolated asthivaha pathology.

9. Majjavaha Srotas

The roots of majjavaha srotas are asthi and sandhi, meaning bones and joints. Majja primarily denotes the substance filling bony cavities and is often translated as marrow. Bone marrow and the contents of internal bony spaces are therefore the safest modern comparison. Equating majjavaha srotas wholesale with the nervous system or claiming a shared embryological origin is inaccurate.

10. Shukravaha Srotas

The roots of shukravaha srotas in Charaka are the testes and shepha, the male genital organ. Shukra is the reproductive dhatu and has broader connotations of reproductive capacity and vitality, but this particular root description is male-specific. It may be compared cautiously with male reproductive structures and semen-forming and conveying functions. Female reproductive channels are described separately in Sushruta under artavavaha srotas.

11. Mutravaha Srotas

The roots of mutravaha srotas are basti and the two vankshanas, commonly translated as bladder and groin regions. Disturbance may involve excessive, obstructed, scanty, frequent, thick, or painful urination. The urinary tract is the closest modern comparison, but the classical root statement should not be rewritten as “kidneys and sweat glands” or treated as a complete map of renal endocrinology.

12. Purishavaha Srotas

The roots of purishavaha srotas are pakvashaya and sthula guda, corresponding broadly to the lower bowel and rectal outlet. Charaka describes difficult, scanty, noisy, painful, excessively liquid, excessively hard, or excessive stool as signs of disturbance. This category is closely comparable to colonic transit, stool formation, and defecation, although biomedical diagnoses such as irritable bowel syndrome cannot be assigned from the srotas label alone.

13. Svedavaha Srotas

The roots of svedavaha srotas are meda and lomakupa, adipose tissue and hair follicles or pores. Disturbance includes absent or excessive sweating, abnormal roughness or smoothness of the body, burning, and horripilation. Sweat production, skin function, and thermoregulation are useful modern comparisons. The classical description does not identify a separate “opening” in the kidneys, nor does it make svedavaha srotas identical with the entire integumentary system.

How Sushruta’s Enumeration Differs

Sushruta’s Sharira Sthana, Chapter 9, gives eleven paired internal srotas in a surgical context: pranavaha, annavaha, udakavaha, rasavaha, raktavaha, mamsavaha, medovaha, mutravaha, purishavaha, shukravaha, and artavavaha. Sushruta does not simply add three more channels to Charaka’s thirteen to create a canonical list of sixteen. The two texts organize the subject differently and sometimes give different root sites because their clinical emphasis differs.

Artavavaha Srotas

Sushruta describes two artavavaha srotas with roots in the garbhashaya and artavavahi dhamanis, the uterus and vessels that carry artava. Injury is associated with infertility, intolerance of intercourse, and loss of menstruation. This may be compared with female reproductive and menstrual pathways, but it is not accurate to list polycystic ovary syndrome, dysmenorrhea, or every menstrual disorder as a direct classical sign of artavavaha injury.

Stanya and Manas in Relation to Srotas

Sushruta counts the two breasts among the additional external openings present in women, and Ayurvedic literature discusses the production and flow of stanya, or breast milk. However, “stanyavaha srotas” is not one of the eleven paired internal srotas listed in Sushruta Sharira 9/12. Likewise, Charaka refers to pathways associated with manas in several contexts, but manovaha srotas is not presented as a fourteenth item with a fixed mula in the thirteen-channel list of Sroto Vimana. It should not be equated directly with the central nervous system, neurotransmitters, or the gut-brain axis.

Classical Summary Table

This table gives the thirteen principal channels in Charaka and one additional female reproductive channel explicitly listed by Sushruta. The modern comparison is deliberately broad and educational.

Srotas	Classical Mula	Cautious Modern Comparison	Classical Indicators or Scope
Pranavaha	Hridaya, mahasrotas	Respiration with cardiopulmonary support	Abnormal, frequent, noisy, restricted, or painful breathing
Udakavaha	Palate, kloma	Thirst, hydration, and fluid regulation	Dry mouth and throat, excessive thirst
Annavaha	Stomach, left flank	Food intake and upper gastrointestinal function	Food aversion, anorexia, indigestion, vomiting
Rasavaha	Heart, ten dhamanis	Nutrient distribution, plasma, lymph, perfusion	Disorders attributed to rasa dhatu
Raktavaha	Liver, spleen	Blood-related and vascular functions	Disorders attributed to rakta dhatu
Mamsavaha	Snayu, skin	Muscle and supporting connective tissues	Disorders attributed to mamsa dhatu
Medovaha	Kidneys, vapavahana	Adipose tissue and metabolic storage	Disorders attributed to meda dhatu
Asthivaha	Meda, pelvic region	Bones and skeletal maintenance	Disorders attributed to asthi dhatu
Majjavaha	Bones, joints	Marrow and contents of bony cavities	Disorders attributed to majja dhatu
Shukravaha	Testes, male genital organ	Male reproductive pathways	Disorders attributed to shukra dhatu
Mutravaha	Bladder, groins	Urinary formation, storage, and passage	Excessive, obstructed, scanty, frequent, thick, or painful urine
Purishavaha	Lower bowel, rectal outlet	Colon, stool formation, and defecation	Difficult, painful, liquid, hard, scanty, or excessive stool
Svedavaha	Adipose tissue, hair follicles	Sweating, skin, and thermoregulation	Absent or excessive sweat, burning, altered skin texture
Artavavaha	Uterus, artava-carrying vessels	Female reproductive and menstrual pathways	Sushruta describes effects of injury, including infertility and loss of menstruation

The Four General Forms of Srotodushti

Charaka gives four general signs of channel morbidity in Vimana Sthana 5/24: atipravritti, sanga, siragranthi, and vimargagamana. These are broad Ayurvedic patterns of disturbed movement or structure. They are not biomedical diagnoses and should not be used to label a specific disease without clinical assessment.

1. Atipravritti

Atipravritti means excessive activity, discharge, or flow. Depending on the affected channel, it may be expressed as an abnormal increase in movement or output, such as excessive stool, urine, sweat, or other discharge. It is safer to understand this as a general pattern than to equate it automatically with tachycardia, hyperventilation, or a particular dosha in every case.

2. Sanga

Sanga means obstruction, retention, arrest, or inadequate passage. Constipation, urinary retention, or impaired movement within a relevant channel can illustrate the idea. The cause may involve dosha, depleted function, inappropriate food or behaviour, structural damage, or other factors described for the individual srotas. Charaka does not state that every sanga is caused primarily by kapha or by a physically measurable substance called ama.

3. Siragranthi

Siragranthi refers to knotting, nodular change, or abnormal swelling in a channel or vessel. It can be used conceptually for localized structural alteration, but the term should not be translated indiscriminately as tumour, fibroid, lipoma, varicose vein, or kidney stone. Each of those conditions requires its own diagnosis and may have multiple Ayurvedic and biomedical explanations.

4. Vimargagamana

Vimargagamana means movement through an improper route or in an abnormal direction. Reflux, leakage, displacement, or diversion may serve as illustrations, but ectopic pregnancy, venous insufficiency, and retrograde menstruation are not stated examples in Charaka’s verse. The clinical meaning depends on what is moving, where it is moving, and which dosha, dhatu, organ, or pathway is involved.

Causes and Clinical Assessment

Charaka lists both a general rule and channel-specific causes. In general, foods and activities whose qualities resemble aggravated doshas and oppose the qualities of the affected dhatus can disturb their srotas. Specific examples include suppression of natural urges and exertion while hungry for pranavaha disturbance; heat, excessive dryness, and severe thirst for udakavaha disturbance; and excessive, untimely, unsuitable food or weakened digestive function for annavaha disturbance. The remaining channels likewise have distinct dietary, behavioural, traumatic, and physiological causes.

Assessment therefore begins with symptoms, causative factors, appetite and digestion, bowel and urinary patterns, tissue state, dosha features, strength, age, constitution, season, and the course of illness. A cluster such as dry skin, constipation, joint symptoms, and anxiety does not by itself establish obstruction in four named srotas. Those complaints may arise from many conditions, including disorders requiring laboratory testing, imaging, psychological assessment, or urgent medical care.

Treatment Principles

Charaka’s treatment directions are organized primarily by the affected channel and its associated disorder, not by a universal one-line remedy for each of the four srotodushti patterns. The text directs treatment of pranavaha, udakavaha, and annavaha disturbance according to the approaches used for shvasa, trishna, and amapradosha. It directs treatment of the dhatu-carrying channels according to the relevant dhatu disorders, and treatment of urinary, fecal, and sweat channels according to the corresponding clinical chapters.

Methods such as langhana, snehana, swedana, shodhana, shamana, dietary correction, regulation of natural urges, or surgical care may be selected only after diagnosis. Vamana, virechana, basti, nasya, and raktamokshana should not be assigned mechanically to named srotas or attempted as home cleansing procedures. Panchakarma and invasive therapies require proper indications, preparation, supervision, and assessment by a qualified Ayurvedic physician.

Modern Physiology: Useful Parallels, Not Validation

Modern anatomy recognizes many interacting transport networks, including blood and lymphatic vessels, ducts, the gastrointestinal and urinary tracts, interstitial fluid spaces, extracellular matrix pathways, and perivascular fluid movement in the brain. Research has also described bidirectional gut-brain communication through neural, immune, endocrine, and microbial mechanisms. These findings make network-based explanations of physiology familiar to modern readers.

Such findings do not prove that the interstitium is srotas, that the glymphatic pathway is manovaha srotas, or that the microbiome validates annavaha theory. The classical categories were created within a different medical system, use different definitions, and include diagnostic and therapeutic concepts not measured by these studies. The responsible approach is comparative: modern physiology may illuminate transport, exchange, and interdependence, while the Ayurvedic model is interpreted on its own textual terms.

Charaka describes srotas as the internal pathways that carry dhatus undergoing transformation and states that their varieties correspond to the many embodied structures and processes of the person. — Charaka Samhita, Vimana Sthana 5/3

This article is for educational purposes. Symptoms such as breathlessness, chest pain, persistent vomiting, inability to pass urine or stool, abnormal bleeding, severe thirst, neurological change, infertility, or menstrual disturbance require assessment by a qualified healthcare professional. Ayurvedic diagnosis and treatment should be individualized by a properly trained practitioner and should not replace indicated biomedical evaluation or emergency care.

References

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.